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SUMMARY
• Polypharmacy – the use of multiple medications within a given period – is common in the United 
States.
• Although polypharmacy as a result of legitimate management of a medical condition is an important 
topic, the focus of this issue brief is on polypharmacy as an aspect of prescription drug misuse. 
• Misuse of prescription opioids has been associated with use of illicit drugs, especially heroin. Results 
from recent studies showed that almost one-half of heroin-injecting individuals abused prescription 
opioids before switching to heroin. 
• Misuse of multiple drugs can lead to adverse effects including addiction; drug-drug interactions; and 
overdose, potentially resulting in death.
• Fatal overdose is the most severe consequence of multiple-drug use. A large share of drug-related 
deaths is attributable to opioids (both prescription and illegal) and also involve multiple substances, 
primarily opioids and benzodiazepines.
• Polypharmacy is also not uncommon in Indiana; almost 84% of prescription drug misusers receiving 
substance abuse treatment reported using at least one additional substance, most commonly alcohol 
or marijuana.
What is Polypharmacy?
Polypharmacy – the use of multiple medications 
within a given period - is common in the United 
States [1]. While there is no universal definition, 
polypharmacy is generally determined based on 
either the number of medications involved or 
whether the usage of the medications is deemed 
unnecessary [2, 3]. Polypharmacy is frequently 
an indicator or consequence of prescription drug 
abuse; however, it can also simply refer to indi-
viduals dealing with multiple health conditions 
who require a variety of medications. 
 An analysis of a nationally representa-
tive multi-year survey showed that over half of 
all U.S. adults (about 117 million individuals) 
were being treated for a minimum of two chron-
ic diseases [4]. Every year about one-third of all 
the prescribed medications in the United States 
are consumed by the elderly [5]. Also, a study of 
Medicaid-dependent youths indicated that up to 
50% of children in outpatient settings and 85% in 
inpatient and residential settings were prescribed 
two or more medications [6, 7]. Polypharmacy, 
regardless of whether it is the result of legitimate 
treatment or prescription drug abuse, can have 
significant negative consequences, such as ad-
verse drug reactions, drug-drug interactions, and 
other complications [3]. Although polypharmacy 
as a result of legitimate management of a medical 
condition is an important topic, the focus of this 
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issue brief is on polypharmacy as an aspect of 
prescription drug abuse.
Prescription Drug Misuse 
Prescription drug misuse has several definitions, 
but all of them describe it as the deliberate use of 
prescribed medications possessing intoxicating or 
mood-altering effects, in manners or for purposes 
different from those intended by the prescription 
providers [8, 9]. Prescription drugs are misused 
for various reasons, including to induce euphoria, 
alter mental states, or increase physical perfor-
mance. Though prescription drugs are frequently 
viewed as “safe,” abuse of these pharmaceuticals 
can result in dependence and addiction [10-12].
 One of the reasons for the rise in prescrip-
tion drug abuse, particularly prescription pain re-
lievers (opioid analgesics), is the accessibility of 
these medications. From 1991 to 2010, the num-
ber of prescriptions for pain-related treatment 
jumped from 30 million to 180 million – a six-fold 
increase [11]. Many individuals who abuse pre-
scription drugs report obtaining them from fam-
ily members or friends for whom the drugs were 
prescribed [13, 14]. Furthermore, the prescription 
drug abuse epidemic is linked to a lack of consum-
er knowledge about the addictive effects of these 
medications. Once they are prescribed by physi-
cians, many patients readily classify them differ-
ently from illegal drugs, and assume that little or 
no risk is involved in taking them [10]. 
 More than 52 million Americans reported 
having abused prescription drugs at some point in 
their lifetime [9, 15]. According to findings from 
the National Survey on Drug Use and Health (NS-
DUH), pain relievers were the most commonly 
Figure 1: Past-month misuse of prescription pain relievers, tranquilizers, stimulants, and sedatives 
among the U.S. population ages 12 or older, by age group (National Survey on Drug Use and Health, 
2015)
Source: Center for Behavioral Health Statistics and Quality, 2016
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abused prescription drug category. Young adults 
ages 18 to 25 years had the highest prevalence 
rates of prescription drug abuse across all catego-
ries (Figure 1) [15]. 
 Pain reliever abuse has been identified 
as the second most common type of drug use in 
the United States, behind marijuana use [16], 
frequently leading to visits to emergency depart-
ments, substance abuse treatment admissions, 
and fatal overdoses [17, 18]. 
 The progression from prescription drug use 
to abuse and addiction is based on different factors 
such as individual vulnerability (e.g., genetics, cer-
tain medical disorders), age, gender, and ease of 
access [12, 19, 20]. Studies have found that med-
ical use of prescription drugs, especially pain re-
lievers, is associated with an increased risk of sub-
sequent illicit use of the drug [21]. Safe initial use 
of these pharmaceuticals tends to lower the user’s 
perceived risk, and therefore, encourages subse-
quent usage [22]. Furthermore, opioid analgesics 
affect the brain by not only producing both pain 
relief and euphoria, but also concurrently forming 
a link between the brain’s receipt of the drugs and 
their perceived effects [23]. This conditioning can 
lead to uncontrollable cravings for the drugs’ ef-
fects, whether for pain relief or euphoria. Medical 
users of prescription opioids for pain management 
are vulnerable to this; the use of prescription opi-
oids often leads to unintended consequences, in-
cluding physical dependence and addiction [24]. 
Physical dependence is a physiological response to 
regular use of a psychoactive substance, in which 
the body requires more and more of the drug to 
achieve the same effect (tolerance) and abrupt ces-
sation of use leads to drug-specific physical and 
mental withdrawal symptoms. Addiction is the 
compulsive and continued use of a drug despite 
harmful consequences. Though dependence is not 
the same as addiction, it generally is a feature of 
addiction [25]. 
 Abuse of prescription opioids has been as-
sociated with use of illicit drugs, especially heroin. 
Results from recent studies showed that almost 
one-half of heroin-injecting individuals abused 
prescription opioids before switching to heroin. 
One of the reasons mentioned for switching was 
that heroin was cheaper and easier to obtain than 
prescription medications [26]. 
Polypharmacy in Indiana’s Substance 
Abuse Treatment Population
The following analyses are based on informa-
tion from Indiana’s Treatment Episode Data Set 
(TEDS). State law requires publicly funded drug 
treatment programs to routinely collect informa-
tion on the number and characteristics of persons 
admitted to their programs and report these data 
to the Indiana Family and Social Services Admin-
istration’s Division of Mental Health and Addic-
tion. TEDS records represent admissions rather 
than individuals; individuals may be admitted to 
treatment more than once in a given year. Several 
limitations of the data have been identified. Only 
publicly funded substance abuse treatment pro-
viders are required to collect and submit client in-
formation. Additionally, Indiana only collects data 
on clients that are at or below the 200% federal 
poverty level. Hence, findings presented in this re-
port may not be representative of the state’s entire 
treatment population. 
 The nonmedical use of prescription drugs 
increased in Indiana’s treatment population from 
19.4% in 2010 to 28.5% in 2016. This increase was 
primarily driven by the rise in the misuse of opi-
oid medications (Figure 2). The problematic use 
of multiple drugs was particularly evident in this 
population group. Use of two or more substances 
was reported in 83.6% of prescription drug misus-
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ers, compared to 54.0% of the rest of the substance 
abuse treatment population. Overall, marijuana 
and alcohol were the most commonly co-used 
substances among prescription drug misusers (see 
Table 1 for a detailed list of the most frequently 
co-used drugs). 
Figure 2: Percentage of Indiana treatment admissions reporting nonmedical use of prescription drugs, by 
drug category (TEDS, 2010-2016)
Source: Indiana Division of Mental Health and Addiction, 2017 
Consequences of Polypharmacy
Prescription drugs that are used illicitly, especially 
when combined with other drugs, pose significant 
health risks, potentially leading to harmful or even 
lethal outcomes [8, 27]. Polypharmacy has been 
linked to greater drug-related problems compared 
to single drug use [28, 29] and is associated with 
poorer mental health, including psychological dis-
tress, anxiety, and depression [30]; risk-taking be-
haviors [31, 32]; and suicide attempts [33].  
 Drugs, whether illicit or pharmaceutical, 
are responsible for 90% of all poisoning deaths 
in the nation [34], and drug overdose mortality 
rates have increased significantly from 12.3 per 
100,000 population in 2010 to 16.3 in 2015 [35]. 
The top 10 drugs involved in overdose deaths in-
clude opioids (fentanyl, heroin, hydrocodone, 
methadone, morphine, and oxycodone), benzodi-
azepines (alprazolam and diazepam), and stimu-
lants (cocaine and methamphetamine) [12]. Pre-
scription pain medications account for much of 
the surge in drug-poisoning or overdose deaths. In 
2015, 63.1% (33,091) of the 52,404 deaths from 
drug overdoses in the United States involved an 
opioid; this represents an increase of nearly 5,000 
opioid-based fatalities from the previous year 
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[35]. According to a study by Warner et al., almost 
half (48%) of the drug overdose deaths in 2014 in-
volved multiple drugs [12]. 
 In Indiana, the number of fatal drug over-
doses increased substantially over the past years, 
resulting in at least 1,236 deaths in 2015; though 
contributing drug(s) were not always identified. 
Of the deaths where at least one specific drug was 
identified, prescription opioids contributed to 274 
Source: Indiana Division of Mental Health and Addiction, 2017
Table 1: Co-use of prescription drugs and other substances in Indiana’s treatment population (TEDS, 
2010-2016)
Co-use of other drugs among patients reporting 
misuse of prescription opioids1
Marijuana 37.6%
Alcohol 29.2%
Prescription sedative/tranquilizers 16.3%
Heroin 15.4%
Methamphetamine 12.9%
Cocaine 12.9%
Prescription stimulants 10.6%
Co-use of other drugs among patients reporting 
misuse of prescription sedatives/tranquilizers2
Marijuana 43.9%
Prescription opioids 41.9%
Alcohol 36.0%
Heroin 14.8%
Methamphetamine 13.4%
Cocaine 6.7%
Prescription stimulants 2.4%
Co-use of other drugs among patients reporting 
misuse of prescription stimulants3
Marijuana 37.2%
Alcohol 30.8%
Prescription opioids 20.8%
Cocaine 18.5%
Heroin 18.3%
Methamphetamine 10.8%
Prescription sedative/tranquilizers 10.6%
deaths and heroin to 239 in 2015 (Figure 3). In 
addition to the deaths, there were 1,430 nonfatal 
hospitalizations due to opioid overdoses in 2015, 
and more than 11,000 nonfatal emergency depart-
ment visits due to opioid overdoses between 2011 
and 2015 (ISDH, 2016). It is important to note 
that a large part of these overdoses, fatal or oth-
erwise, likely resulted from use of multiple drugs 
[12].  
1 We used TEDS variables “nonprescription methadone” and “other opiates/synthetics” to define the prescription opioids category (excludes heroin).
2 We used TEDS variables “benzodiazepines,” “other tranquilizers,” “barbiturates,” and “other sedatives/hypnotics” to define the prescription sedatives/tranquilizers 
category.
3 We used TEDS variables “other amphetamines” and “other stimulants” to define the prescription stimulants category.
Source: Indiana Division of Mental Health and Addiction, 2017
Source: Indiana Division of Mental Health and Addiction, 2017
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Figure 3: Drug overdose deaths involving opioid pain relievers and other drugs, Indiana, 2006-2015
Conclusion
Polypharmacy, i.e., the misuse of multiple prescription 
drugs or prescription medication with other substanc-
es, is highly problematic. Whether unintentional or de-
liberate, misuse of multiple drugs can lead to adverse 
effects including addiction; drug-drug interactions; 
and overdose, potentially resulting in death. Polyphar-
macy is not uncommon; almost 84 percent of prescrip-
tion drug misusers receiving substance abuse treat-
ment in Indiana reported using at least one additional 
substance, most commonly alcohol or marijuana. 
 Fatal overdose is the most severe consequence 
of multiple-drug use. A large share of drug-related 
deaths is attributable to opioids (both prescription and 
illegal) and also involves multiple substances, primari-
ly opioids and benzodiazepines [36].
 Despite efforts at the federal, state, and local 
levels to contain the problem of prescription drug 
misuse, the issue persists. The problem is quite com-
plex, especially since many people’s treatment relies 
on prescription drugs that are legitimately prescribed 
by their health care providers. The fact that misuse of 
prescription drugs can arise from both legitimate and 
illegitimate sources hampers efforts to create legisla-
tion to address the problem. 
Note: Based on ICD-10 drug overdose/poisoning underlying causes of death X40-X44, X60-X64, X85, or 
Y10-Y14, as well as contributing causes of T40.2-T40.4 (prescription opioids), T40.1 (heroin), T40.6 (other 
and unspecified narcotics), and T42.4 (benzodiazepines).
Source: ISDH, 2017
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